Hal V. Barron

Last updated
Hal V. Barron
Alma mater Washington University in St. Louis,
Yale University, University of California, San Francisco
Scientific career
Fields Physician
Institutions University of California, San Francisco (UCSF), Calico (company), Genentech, Hoffmann-La Roche

Hal V. Barron (born 1962) is an American clinician-scientist and drug developer who served as president of research and development at GlaxoSmithKline from March 2018 [1] until 2022, when he resigned in order to join the cellular reprogramming venture Altos Labs in August of that year. [2] [3] [4] Prior to this he served as president of research and development at Calico. [5] He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche. [6]

Contents

Career

Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. [7] In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.

On September 18, 2013, Barron was named President of Research and Development of Calico, a new company focusing on the biology of aging. [8] The company was created and funded by Google. [9]

On November 8, 2017, Barron became the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley. Barron was quoted: "GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.” [10]

In April 2019, it was publicly reported that Barron spent excessively on travel expenses during the previous year. The total expenses exceeded $807,000 (£620,000). Shareholders, investors, and rank-and-file employees have all expressed concern tilting towards outrage that he has been allow to spend so freely while others are constrained and employee layoffs continue.

In January 2022, it was announced that Barron will join Altos starting on 1 August 2022 at newly created biotech company Altos Labs, based in San Francisco. [4]

Barron's current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 80 papers in peer-reviewed scientific journals. [11] He was a member of the board of directors at Alexza Pharmaceuticals, and is a current member of the board of directors at Juno Therapeutics. [12]

Education

Barron received his medical degree from Yale University and holds a Bachelor of Science degree in engineering physics from Washington University. He completed his training in medicine and cardiology at the University of California, San Francisco.

Related Research Articles

GSK plc British multinational pharmaceutical and biotechnology company

GSK plc, formerly GlaxoSmithKline plc, is a British American multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck Sharp & Dohme (MSD). GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune Global 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck and Sanofi.

Exelixis American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Human Genome Sciences Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

Arthur D. Levinson is an American businessman and is the current chairman of Apple Inc. (2011–present) and CEO of Calico. He is the former chief executive officer (1995–2009) and chairman (1999–2014) of Genentech.

Andrew Witty British business executive (born 1964)

Sir Andrew Philip Witty is a British business executive, who is the current chief executive officer (CEO) of UnitedHealth Group. He was also the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US.

Darapladib Chemical compound

Darapladib is an inhibitor lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis.

Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and serial entrepreneur Andrew Perlman, and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab.

Christoph Westphal, M.D., Ph.D., is a biomedical entrepreneur.

Stiefel Laboratories American corporation

Stiefel Laboratories is an American dermatological pharmaceutical company, with its global headquarters in Research Triangle Park, North Carolina. It makes products such as Duac and Oilatum. Stiefel was acquired by GlaxoSmithKline at a price of $2.9 billion. The company was founded in 1847 by John David Stiefel, Ferdinand von Hebra and Paul Unna, who initially created medicated soaps.

Marc Tessier-Lavigne Canadian neuroscientist

Marc Trevor Tessier-Lavigne is a Canadian-born neuroscientist who is the 11th and current President of Stanford University. He holds dual citizenship of the United States and Canada. Previously, he was a professor at the University of California, San Francisco and then president of Rockefeller University in New York City. He was formerly Executive Vice President for research and the Chief Scientific Officer at Genentech. He was the first industry executive to assume the Rockefeller presidency. He is also a member of the Cure Alzheimer's Fund's Scientific Advisory Board. As of 2021, he is on the boards of directors of Denali Therapeutics and Regeneron Pharmaceuticals, as well as the scientific advisory boards of Denali Therapeutics and Agios Pharmaceuticals.

Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.

Calico Life Sciences LLC is an Alphabet subsidiary responsible for health research and development, life sciences and biotechnology. Originating on September 18, 2013 prior to the Google restructuring and headed by Bill Maris with the goal of combating aging and diseases of aging, it was incorporated into Alphabet with Google's other sister divisions in 2015.

Verily Life sciences research organization

Verily Life Sciences, also known as Verily, is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. This restructuring process was completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.

Amicus Therapeutics Pharmaceutical company

Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

Emma Walmsley British businesswoman

Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up Barrow-in-Furness, Cumbria, England.

Galvani Bioelectronics is a Stevenage, United Kingdom-based bioelectronics R&D company.

Paul-Peter Tak is an immunologist and academic specialising in the fields of rheumatology and immunology. In addition to academic research, he served as an executive of several pharmaceutical companies.

Moncef Slaoui Moroccan-American-Belgian doctor and researcher

Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the Head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.

References

  1. ↑ "Wires". Cnbc.com. Retrieved 13 February 2019.
  2. ↑ Carroll, John (January 19, 2022). "What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain". Endpoints News . Retrieved 19 June 2022.
  3. ↑ "Altos Labs: Executive Leadership". Altos Labs . Retrieved 19 June 2022.
  4. 1 2 Kollewe, Julia (19 January 2022). "GSK's top scientist jumps ship in new blow for pharmaceutical firm". The Guardian . Retrieved June 19, 2022.
  5. ↑ "I'm excited to announce Calico, a new company that will focus on health and w..." Plus.google.com. Retrieved 13 February 2019.
  6. ↑ "Archived copy". Archived from the original on 2009-04-19. Retrieved 2014-06-04.{{cite web}}: CS1 maint: archived copy as title (link)
  7. ↑ "Genentech: Press Releases - Tuesday, May 14, 2002". Gene.com. Retrieved 13 February 2019.
  8. ↑ "Home". calicolabs.com.
  9. ↑ "Google announces Calico, a new company focused on health and well-being – News announcements – News from Google – Google". Googlepress.blogspot.com. Retrieved 13 February 2019.
  10. ↑ "Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out - FierceBiotech". Fiercebiotech.com. 8 November 2017. Retrieved 13 February 2019.
  11. ↑ "Pubmed search" . Retrieved 15 April 2019.
  12. ↑ "Hal Barron – Juno Therapeutics". Junotherapeutics.com. Retrieved 13 February 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.